novel
class
human
monoclon
antibodi
influenza
recent
discov
antibodi
bind
membraneproxim
stem
haemagglutinin
major
viral
surfac
protein
neutral
influenza
viru
block
fusion
host
cell
panel
antibodi
similar
mode
action
report
subsequ
sui
et
al
due
high
conserv
recognit
site
class
antibodi
shown
abil
neutral
broad
spectrum
influenza
subtyp
includ
expect
also
neutral
virus
subtyp
well
futur
antigen
drift
variant
one
antibodi
investig
mice
shown
protect
given
lethal
challeng
viru
suggest
potenti
firstev
broadspectrum
monoclon
antibodi
prophylaxi
treatment
influenza
viru
infect
accord
world
health
organ
season
influenza
caus
death
worldwid
year
immunolog
infant
immunocompromis
individu
elderli
particularli
suscept
ill
caus
season
influenza
virus
death
occur
latter
group
addit
subtyp
influenza
virus
previous
circul
among
human
occasion
cross
anim
reservoir
rais
spectr
pandem
past
decad
promin
pandem
threat
appear
pose
highli
pathogen
avian
influenza
virus
subtyp
howev
new
strain
human
emerg
mexico
unit
state
march
april
rapidli
spread
across
globe
caus
declar
pandem
june
although
virul
viru
current
moder
particularli
compar
case
fatal
rate
human
infect
may
chang
time
meanwhil
threat
highli
pathogen
avian
virus
persist
continu
circul
evolv
bird
popul
prevent
vaccin
histor
primari
mean
influenza
control
approach
import
limit
vaccin
typic
elicit
potent
neutral
antibodi
respons
specif
viral
strain
contain
close
relat
virus
furthermor
influenza
vaccin
suboptim
immunogen
efficaci
group
highest
risk
sever
diseas
young
elderli
immunocompromis
individu
current
therapeut
regimen
influenza
limit
two
class
drug
adamantan
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
adamantan
rapidli
elicit
viral
resist
resist
rate
high
among
virus
certain
clade
virus
use
oseltamivir
lead
antivir
influenza
drug
limit
sudden
widespread
emerg
resist
among
circul
influenza
strain
oseltamivir
resist
also
observ
treatment
infect
zanamivir
still
effect
virus
resist
drug
less
like
aris
howev
use
limit
patient
activ
use
inhal
drug
exclud
young
children
impair
older
adult
patient
underli
airway
diseas
group
patient
vulner
seriou
complic
influenza
infect
absenc
reliabl
antivir
drug
vaccin
develop
altern
strategi
influenza
prophylaxi
therapi
urgent
requir
order
assess
whether
may
viabl
option
human
treatment
evalu
prophylact
therapeut
efficaci
human
monoclon
antibodi
highli
stringent
lethal
influenza
ferret
model
ferret
suitabl
diseas
model
human
influenza
infect
display
humanlik
diseas
four
group
ferret
receiv
mgkg
via
intraven
inject
challeng
next
day
highli
pathogen
avian
viru
control
group
ferret
receiv
mgkg
irrelev
isotypematch
antibodi
ferret
receiv
mgkg
surviv
compar
control
anim
figur
reduct
dose
mgkg
clearli
correl
lower
surviv
rate
though
statist
signific
differ
surviv
observ
control
anim
mortal
reduct
lowest
dose
mgkg
associ
surviv
benefit
compar
control
anim
surviv
time
differ
significantli
group
receiv
mgkg
control
group
p
moribund
anim
show
gener
depress
anorexia
lethargi
exhibit
clinic
sign
respiratori
diseas
includ
dyspnoea
anim
treat
efficaci
dose
level
mgkg
loos
bodi
weight
wherea
mean
weight
loss
control
group
time
ferret
die
euthan
figur
except
one
control
ferret
succumb
infect
within
hour
challeng
lost
hardli
weight
ferret
receiv
mgkg
show
similar
declin
bodi
weight
control
anim
one
day
challeng
maximum
bodi
temperatur
observ
ferret
maximum
bodi
temperatur
depict
figur
group
treat
mgkg
mean
temperatur
respect
significantli
lower
mean
observ
control
group
p
p
respect
mean
temperatur
observ
anim
treat
lower
dose
mgkg
respect
differ
significantli
control
group
mean
temperatur
anim
observ
day
challeng
similar
across
group
rang
individu
bodi
temperatur
vari
consider
within
one
healthi
ferret
hour
standard
deviat
ferret
treat
mgkg
shed
infecti
viru
upper
respiratori
tract
time
wherea
anim
control
group
figur
treatment
mgkg
prevent
shed
reduc
proport
ferret
infecti
viru
nasal
andor
throat
swab
necropsi
ferret
assess
viral
load
lung
figur
anim
receiv
mgkg
control
antibodi
also
assess
viral
load
brain
liver
spleen
blood
kidney
level
viru
replic
lung
ferret
treat
mgkg
lower
control
group
p
infecti
viru
detect
organ
ferret
receiv
mgkg
wherea
infecti
viru
found
brain
liver
spleen
control
anim
data
shown
signific
differ
lung
viral
load
group
receiv
mgkg
compar
control
group
p
p
respect
histopatholog
result
accord
find
describ
anim
receiv
mgkg
show
much
less
pulmonari
lesion
primari
atyp
pneumonia
subacut
bronch
iol
iti
emphysema
congest
show
lesion
lower
grade
sever
compar
anim
group
bronchiol
obliteran
observ
anim
receiv
mgkg
compar
higherdos
group
anim
receiv
mgkg
show
regen
respons
diffus
greyr
area
bronchioloalveolar
hyperplasia
lung
inflammatori
chang
trachea
pulmonari
oedema
observ
anim
receiv
mgkg
observ
frequent
group
find
agreement
mean
lung
weight
lowest
anim
treat
mgkg
g
g
respect
significantli
lower
group
control
anim
g
comparison
p
signific
differ
lung
weight
found
group
receiv
mgkg
g
g
respect
control
group
g
find
show
dose
depend
way
prophylact
administ
confer
protect
lethal
challeng
prevent
morbid
viral
dissemin
reduc
pulmonari
patholog
assess
therapeut
efficaci
monoclon
antibodi
two
group
ferret
challeng
given
mgkg
either
hour
later
compar
group
ferret
receiv
mgkg
control
antibodi
hour
challeng
surviv
rate
group
receiv
hour
challeng
wherea
anim
control
group
surviv
p
figur
mean
declin
bodi
weight
end
experi
group
ferret
receiv
hour
challeng
figur
significantli
less
p
observ
control
anim
anim
treat
hour
post
challeng
show
mean
bodi
weight
loss
significantli
differ
control
anim
p
group
ferret
treat
hour
post
challeng
mean
maximum
temperatur
compar
control
group
p
line
rapid
rise
temperatur
challeng
observ
prophylaxi
experi
ferret
treat
hour
challeng
show
mean
maxim
temperatur
administ
p
versu
control
group
figur
ferret
treat
hour
post
challeng
shed
infecti
viru
upper
respiratori
tract
throughout
studi
figur
group
treat
hour
post
challeng
one
ferret
low
concentr
infecti
viru
throat
day
one
viru
detect
subsequ
day
contrast
anim
control
group
shed
viru
one
day
accordingli
mean
viral
load
lung
ferret
treat
hour
post
challeng
consider
lower
control
group
differ
respect
comparison
p
figur
lung
anim
receiv
hour
post
challeng
show
less
pulmonari
lesion
alveolar
oedema
bronchiol
obliteran
congest
emphysema
bronchioloalveolar
hyperplasia
primari
atyp
pneumonia
show
lesion
lower
grade
sever
compar
lung
anim
two
group
anim
control
group
affect
primari
atyp
pneumonia
find
accord
observ
mean
lung
weight
ferret
treat
hour
post
challeng
lower
compar
control
group
g
versu
g
p
figur
anim
receiv
hour
post
challeng
show
regen
respons
bronchioloalveolar
hyperplasia
lung
suggest
damag
lung
parenchyma
subsequ
regen
respons
mean
lung
weight
group
significantli
higher
group
receiv
hour
post
challeng
g
versu
g
lower
control
group
p
studi
outset
one
anim
ad
two
treatment
group
sacrif
grosspatholog
histolog
lung
soon
control
anim
die
purpos
test
possibl
bia
due
differ
time
death
infecti
viru
titr
lung
treat
ferret
sacrif
day
ident
treat
anim
sacrif
end
studi
open
circl
figur
similarli
differ
lung
weight
patholog
anim
sacrif
day
day
figur
indic
result
bias
differ
time
euthanasia
spontan
death
repres
new
class
human
monoclon
antibodi
exhibit
immedi
potent
efficaci
prevent
treatment
influenza
clinic
relev
model
sever
diseas
result
present
also
confirm
previous
report
data
demonstr
prophylact
therapeut
efficaci
mice
challeng
influenza
virus
togeth
challeng
mice
data
publish
earlier
find
indic
effect
across
broad
spectrum
influenza
virus
includ
season
potenti
pandem
strain
passiv
immunotherapi
would
particularli
benefici
group
highest
risk
sever
diseas
due
season
elderli
may
also
indispens
gener
public
event
pandem
diseas
outbreak
caus
highrisk
pandem
candid
monoclon
antibodi
influenza
virus
studi
decad
thu
passiv
immunotherapi
influenza
inhibit
lack
monoclon
antibodi
broad
neutral
activ
lack
due
toler
influenza
viru
genet
chang
immunogen
region
surfac
recent
discoveri
broadli
neutral
human
monoclon
influenza
antibodi
demonstr
efficaci
repres
novel
class
antibodi
lethal
viral
challeng
clinic
relev
model
present
paper
creat
opportun
prevent
treatment
influenza
infect
regardless
causal
strain
possibl
potent
broadli
neutral
agent
would
equip
clinician
public
health
worker
deal
effect
influenza
virus
futur
repres
paradigm
shift
approach
influenza
control
influenza
ill
observ
ferret
infect
viru
studi
close
resembl
influenza
human
infect
present
fever
cough
short
breath
radiolog
evid
pneumonia
besid
respiratori
symptom
gastrointestin
symptom
diarrhoea
vomit
abdomin
pain
often
present
sever
case
pneumonia
rapidli
progress
acut
respiratori
distress
syndrom
multiorgan
failur
high
viral
load
extrapulmonari
viru
dissemin
hypercytokinaemia
associ
fatal
outcom
review
autopsi
patient
succumb
influenza
viru
infect
shown
diffus
alveolar
damag
patchi
interstiti
lymphoplasmacyt
infiltr
bronchiol
squamou
metaplasia
pulmonari
congest
variou
degre
haemorrhag
clinic
sign
observ
control
anim
ferret
studi
correspond
sever
influenza
patholog
human
efficaci
prevent
clinic
sign
prophylact
therapeut
ferret
model
present
togeth
efficaci
shown
mice
lethal
challeng
differ
virus
strongli
indic
expect
efficaci
diseas
caus
less
virul
virus
neutral
vitro
metaanalysi
experiment
influenza
infect
placebotr
untreat
healthi
volunt
carrat
et
al
studi
particip
challeng
either
influenza
type
b
interestingli
viral
shed
highli
correl
presenc
clinic
symptom
fever
runni
nose
sore
throat
sneez
cough
short
breath
author
conclud
metaanalysi
subject
symptomat
ill
shed
viru
amount
fold
higher
subject
ill
fact
intraven
administr
instantan
reduc
viral
shed
indic
man
might
reduc
clinic
symptom
subject
infect
influenza
viru
addit
studi
guinea
pig
show
reduct
nasal
wash
titer
correl
decreas
effici
viral
transmiss
aerosol
abil
abolish
shed
viru
pharyng
secret
strongli
suggest
antibodi
like
might
prevent
reduc
viru
spread
onset
epidem
influenza
outbreak
nurs
home
case
pandem
studi
assess
efficaci
human
monoclon
antibodi
highli
pathogen
avian
viru
provid
stringent
diseas
model
sever
influenza
howev
potenti
use
antibodi
limit
virus
subtyp
avian
strain
may
pose
pandem
threat
shown
recogn
virus
emerg
time
span
year
viru
caus
spanish
flu
pandem
latest
brisban
virus
sinc
epitop
conserv
predict
bind
futur
antigen
drift
variant
mean
could
use
protect
influenza
virus
includ
one
resist
oseltamivir
use
combin
effect
medic
oseltamivir
zanamivir
would
effect
protect
season
influenza
virus
without
need
prior
knowledg
viru
subtyp
strain
present
studi
ferret
challeng
inoculum
probabl
much
higher
compar
viral
exposur
natur
infect
human
rapid
deterior
ferret
death
occur
within
day
underpin
hypothesi
sinc
human
expos
develop
first
symptom
day
last
exposur
even
period
day
report
clinic
sign
model
quit
extrem
import
establish
efficaci
antibodi
proof
concept
data
two
experi
demonstr
prophylact
therapeut
efficaci
new
class
human
monoclon
antibodi
highli
stringent
clinic
relev
ferret
model
human
influenza
human
monoclon
antibodi
isol
igm
b
cell
repertoir
healthi
individu
recent
vaccin
season
influenza
vaccin
use
phage
display
select
recombin
haemagglutinin
isotypematch
antibodi
abil
neutral
sar
corona
similar
tissueorgan
tropism
use
control
antibodi
antibodi
produc
cell
studi
perform
outbr
ferret
mustela
putoriu
furo
femal
age
approxim
month
schimmel
farm
uddel
netherland
ferret
screen
presenc
serum
antibodi
aleutian
diseas
viru
circul
season
influenza
viru
strain
b
challeng
viru
seroneg
anim
use
studi
anim
hous
studi
group
prophylact
experi
therapeut
experi
antibodi
administ
intraven
inject
jugular
vein
viral
challeng
perform
intratrach
ml
pb
clinic
observ
perform
twice
day
day
intervent
daili
day
prophylact
experi
anim
weigh
week
viral
challeng
day
immedi
prior
antibodi
administr
day
challeng
day
day
prematur
death
therapeut
experi
anim
weigh
day
day
immedi
prior
challeng
antibodi
administr
day
last
studi
day
bodi
temperatur
record
everi
minut
throughout
experi
use
devic
dst
microt
staroddi
reykjavik
iceland
implant
periton
caviti
day
challeng
anim
experi
carri
central
anim
facil
netherland
vaccin
institut
nvi
bilthoven
condit
meet
dutch
legal
requir
anim
experiment
accord
guid
care
use
laboratori
anim
recommend
institut
laboratori
anim
research
us
nation
institut
health
associ
assess
accredit
laboratori
anim
care
intern
aaalac
standard
viral
titrat
perform
describ
elsewher
briefli
pharyng
nasal
swab
collect
anim
day
day
day
day
individu
swab
homogen
resuspend
ml
medium
store
analysi
viral
titr
determin
viru
titrat
madin
darbi
canin
kidney
mdck
cell
viral
shed
upper
respiratori
tract
analys
calcul
proport
ferret
detect
level
infecti
viru
nasal
andor
throat
swab
rel
number
live
ferret
necropsi
cranioventr
craniodors
caudoventr
caudodors
section
right
lung
collect
anim
weigh
homogen
resuspend
ml
medium
store
analysi
viral
titr
determin
thaw
tissu
section
follow
homogen
resuspens
viru
titrat
mdck
cell
addit
viral
titr
tissu
brain
spleen
liver
kidney
plasma
anim
receiv
either
mgkg
one
day
prior
challeng
determin
use
method
complet
macroscop
postmortem
examin
perform
anim
includ
examin
extern
surfac
orific
thorac
abdomin
pelvic
caviti
associ
organ
tissu
neck
associ
organ
tissu
lung
weigh
lung
lobe
inspect
lesion
describ
left
lung
includ
trachea
collect
autopsi
inflat
neutral
buffer
formalin
fixationhistolog
microscop
examin
paraffin
embed
tissu
section
left
cranial
lobe
left
caudal
lobe
right
cranial
middl
caudal
lobe
accessori
lobe
stain
haematoxylin
eosin
assess
light
microscopi
aspect
like
congest
emphysema
presenc
foreign
bodi
haemorrhagi
bronchioloalveolar
hyperplasia
inflamm
oedema
prior
blood
sampl
take
nose
throat
swab
euthanasia
ferret
anaesthetis
ketamin
mgkg
im
implant
temperatur
sensor
antibodi
administr
viral
challeng
anim
anaesthet
mixtur
ketamin
mgkg
im
domitor
im
follow
antisedan
mgkg
im
surviv
time
viral
challeng
analys
use
logrank
test
surviv
proport
use
fisher
exact
test
bodi
weight
express
percentag
chang
baselin
calcul
end
studi
period
earlier
event
earlier
death
maximum
bodi
temperatur
observ
day
one
valu
subsequ
use
calcul
mean
maximum
bodi
temperatur
group
variabl
analys
oneway
analysi
varianc
anova
posthoc
test
compar
control
group
use
dunnett
adjust
multipl
comparison
lung
weight
lung
viral
titr
compar
across
arm
use
anova
day
necropsi
enter
covari
differ
treatment
group
estim
use
margin
mean
sidak
adjust
multipl
comparison
statist
analys
perform
use
spss
version
spss
inc
usa
statist
signific
level
set
